Observational studyBMC cancer2026
Longitudinal assessment of chemotherapy-induced peripheral neuropathy in women undergoing taxane-based treatment for breast cancer: a prospective observational study.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05441722 (Feasibility of Neurophysiological Assessments and Exercise Prehabilitation in Breast Cancer Patients Receiving Taxane-based Chemotherapy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility of Neurophysiological Assessments and Exercise Prehabilitation in Breast Cancer Patients Receiving Taxane-based Chemotherapy: a Pilot Randomised Controlled Trial
Who cites it
1 citing paper in PubMed.
- Cancer pain.Nature reviews. Disease primers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of taxane-based chemotherapy. However, its trajectory during and after treatment remains poorly understood. This study aimed to estimate the natural history of CIPN symptoms using patient-reported and objective measures.
methodsWomen with stage I-III breast cancer scheduled to receive taxane-based chemotherapy underwent CIPN assessments at five timepoints (pre-chemotherapy, post-anthracycline, mid-taxane, post-taxane, and 6-month follow-up) using physical function tests, patient-reported outcomes, quantitative sensory testing, H-reflex assessments, and static balance testing. Data were analysed using linear mixed models.
resultsTwelve participants enrolled (48% of eligible patients, 100% retention). Self-reported autonomic (all timepoints), motor (post-anthracycline and post-taxane) and sensory (post-taxane and 6-month follow-up) symptoms were greater than pre-chemotherapy (all p < 0.05). Health-related quality of life was impaired at all timepoints compared to pre-chemotherapy. Maximal H-reflex amplitude normalised to maximal M-wave amplitude (Hmax/Mmax) decreased post-taxane (-0.23, 95% CI -0.36 to -0.10, p = 0.001) and at 6-month follow-up (-0.27, 95% CI -0.39 to -0.16, p < 0.001). Anterior-posterior (mid-taxane: 8 mm, 95% CI 2 to 13 mm, p = 0.007; post-taxane: 9 mm, 95% CI 4 to 15 mm, p = 0.001) and total (mid-taxane, p <0.001; post-taxane, p <0.001) sway increased from pre-chemotherapy, but mediolateral sway did not change (all timepoints p ≥ 0.05).
conclusionsComprehensive CIPN assessment during and after chemotherapy is feasible and reveals impairments in nerve function and balance.
trial registrationClinicalTrials.gov Identifier: NCT05441722
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.